The ErbB family is implicated in mediating oncogenesis of epithelial-derived cancers and is reported to be overexpressed in approximately 20–30% of invasive breast cancers, more specifically in high grade ductal carcinoma in situ (DCIS) along with other oncogenes, cyclin D1 at 40–50% [15], and c-myc at 15–25% [16]. Here, EGFR is linked to ductal breast carcinoma in situ.